KCT0001138
Recruiting
未知
Survey for the development of terminal cancer patients' quality of death evaluation tool among bereaved families
CC Hospital0 sites250 target enrollmentTBD
ConditionsNot Applicable
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not Applicable
- Sponsor
- CC Hospital
- Enrollment
- 250
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •terminal cancer patients' bereaved family who participate in the 54 hospice and palliative care organization bereavement family union
- •\-People who is mentally and physically in good condition
- •\-People who agree to participate
Exclusion Criteria
- •\-People who disagree to participate
- •\-People who is not mentally and physically in good condition
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
An evaluation and an examination of the cancer immunology for resectable non-small cell lung cancerPatients with resectable non-small cell lung cancer who are going to receive pulmonary resectionJPRN-UMIN000031128Tohoku Medical and Pharmaceutical University, Tohoku Medical and Pharmaceutical University Hospital20
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab alone or in combination with other cancer therapies.pan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-PLBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab alone or in combination with other cancer therapies.pan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-ATBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab alone or in combinationwith other cancer therapies.EUCTR2018-004362-34-HUBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab alone or in combination with other cancer therapies.pan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-DEBristol-Myers Squibb International Corporation1,231